Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21)

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 1, 2013, Pages 29-44

  Tamai, Ikumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

carnitine; carnitine deficiency; OCTN; organic cation; SLC22A4; SLC22A5; tetraethylammonium; transporter

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARNITINE; CEFALORIDINE; CISPLATIN; IMATINIB; LONG CHAIN FATTY ACID; MELDONIUM; MEPYRAMINE; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; OXALIPLATIN; QUINIDINE; SPIRONOLACTONE; TRANSCRIPTION FACTOR RUNX1; VALPROIC ACID; VERAPAMIL;

AMINO ACID TRANSPORT; APICAL MEMBRANE; AREA UNDER THE CURVE; ASTHMA; AUTOIMMUNE DISEASE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CARDIOMYOPATHY; CARNITINE DEFICIENCY; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; DRUG SELECTIVITY; DRUG TRANSPORT; FATTY ACID OXIDATION; FATTY LIVER; GENE MUTATION; GERM CELL; GLOMERULUS FILTRATION; HEART; HUMAN; INTESTINE; INTESTINE ABSORPTION; KIDNEY; KIDNEY TUBULE ABSORPTION; LIVER; MALE GENITAL SYSTEM; MALE INFERTILITY; MAMMARY GLAND; MOLECULAR RECOGNITION; MUSCLE WEAKNESS; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOLOGY; PHENOTYPE; PLACENTA; PROTEIN ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; CARDIOMYOPATHIES; CARNITINE; CARRIER PROTEINS; HUMANS; HYPERAMMONEMIA; INTESTINAL ABSORPTION; MALE; MEMBRANE PROTEINS; MICE; MUSCULAR DISEASES; MUTATION; ORGANIC CATION TRANSPORT PROTEINS;

EID: 84872688669     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1816     Document Type: Review

References (100)

1. Giacomini KM, Huang SM, Tweedie DJ, et al,. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236.
2. Tamai I, Yabuuchi H, Nezu J, et al,. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 1997; 419: 107-111.
3. Tamai I, Ohashi R, Nezu J, et al,. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998; 273: 20378-20382.
4. Tamai I, Ohashi R, Nezu J, et al,. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem 2000; 275: 40064-40072.
5. Nezu J, Tamai I, Oku A, et al,. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nature Genet 1999; 21: 91-94.
6. Tamai I, Nakanishi T, Kobayashi D, et al,. Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. Mol Pharm 2004; 1: 57-66.
7. Gründemann D, Harlfinger S, Golz S, et al,. Discovery of ergothioneine transporter. Proc Natl Acad Sci USA 2005; 102: 5256-5261.
8. Nakamura T, Yoshida K, Yabuuchi H, Maeda T, Tamai I,. Functional characterization of ergothioneine transport by rat organic cation/carnitine transporter Octn1 (slc22a4). Biol Pharm Bull 2008; 31: 1580-1584.
9. Tokuhiro S, Yamada R, Chang X, et al,. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 2003; 35: 341-348.
10. Maeda T, Hirayama M, Kobayashi D, Miyazawa K, Tamai I,. Mechanism of the regulation of OCTN1 transporter (SLC22A4) by rheumatoid arthritis-associated transcriptional factor RUNX1 and inflammatory cytokines. Drug Metab Dispos 2007; 35: 394-401.
11. Peltekova VD, Wintle RF, Rubin LA, et al,. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004; 36: 471-475.
12. Kato Y, Kubo Y, Iwata D, et al,. Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. Pharm Res 2010; 27: 832-840.
13. Yabuuchi H, Tamai I, Nezu J, et al,. Novel membrane transporter OCTN1 mediates multispecific, bidirectional and pH-dependent transport of organic cations. J Pharmacol Exp Ther 1999; 289: 768-773.
14. Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ,. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther 2011; 338: 537-547.
15. Urban TJ, Brown C, Castro RA, et al,. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 2008; 83: 416-421.
16. Longo N, Amat di san Filippo C, Pasquali M,. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semi Med Genet 2006; 142C: 77-85.
17. Koizumi T, Nikaido H, Hayakawa J, Nonomura A, Yoneda T,. Infantile disease with microvesicular fatty infiltration of viscera spontaneously occurring in the C3H-H-2 strain of mouse with similarities to Reye's syndrome. Lab Anim 1988; 22: 83-87.
18. Yokogawa K, Higashi Y, Tamai I, et al,. Decreased tissue distribution of l -carnitine in juvenile visceral steatosis mice. J Pharmacol Exp Ther 1999; 289: 224-230.
19. Hashimoto N, Suzuki F, Tamai I, et al,. Gene-dose effect on carnitine transport activity in embryonic fibroblasts of JVS mice as a model of human carnitine transporter deficiency. Biochem Pharmacol 1998; 55: 1729-1732.
20. Bremer J,. Carnitine-metabolism and functions. Physiol Rev 1983; 63: 1420-1480.
21. Horiuchi M, Yoshida H, Kobayashi K, et al,. Cardiac hypertrophy in juvenile visceral steatosis (jvs) mice with systemic carnitine deficiency. FEBS Lett 1993; 326: 267-271.
22. +-coupled transport of l -carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney. Biochim Biophys Acta 2011; 1512: 273-284.
23. Cano MM, Calonge ML, Ilundain AA,. Expression of OCTN2 and OCTN3 in the apical membrane of rat renal cortex and medulla. J Cell Physiol 2010; 223: 451-459.
24. Nakanishi T, Fukushi A, Sato M, et al,. Functional characterization of apical transporters expressed in rat proximal tubular cells (PTCs) in primary culture. Mol Pharm 2011; 8: 2142-2150.
25. Lash LH, Putt DA, Cai H,. Membrane transport function in primary cultures of human proximal tubular cells. Toxicology 2006; 228: 200-218.
26. Kato Y, Sai Y, Yoshida K, Watanabe C, Hirata T, Tsuji A,. PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. Mol Pharmacol 2005; 67: 734-743.
27. Shaw RD, Li BUK, Hamilton JW, Shug AL, Olsen WA,. Carnitine transport in rat small intestine. Am J Physiol 1983; 245: G376-G381.
28. Hamilton JW, Li BUK, Shug AL, Olsen WA,. Carnitine transport in human intestinal biopsy specimens. Gastroenterology 1986; 91: 10-16.
29. Li BUK, Bummer PM, Hamilton JW, Gudjonsson H, Zografi G, Olsen WA,. Uptake of l -carnitine by rat jejuna brush border microvillous membrane vesicles. Evidence of passive diffusion. Dig Dis Sci 1990; 35: 333-339.
30. McCloud E, Ma TY, Grant KE, Mathis RK, Said HM,. Uptake of l -carnitine by human intestinal epithelial cell line, Caco-2. Gastroenterology 1996; 111: 1534-1540.
31. Meier Y, Eloranta JJ, Darimont J, et al,. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 2007; 35: 590-594.
32. Terada T, Shimada Y, Pan X, et al,. Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochem Pharmacol 2005; 70: 1756-1763.
33. Kato Y, Sugiura M, Sugiura T, et al,. Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. Mol Pharmacol 2006; 70: 829-837.
34. Sugiura T, Kato Y, Wakayama T, et al,. PDZK1 regulates two intestinal solute carriers (Slc15a1 and Slc22a5) in mice. Drug Metab Dispos 2008; 36: 1181-1188.
35. Siliprandi N, Sartorelli L, Ciman M, Di Lisa F,. Carnitine: metabolism and clinical chemistry. Clin Chim Acta 1989; 183: 3-11.
36. Grube M, Meyer zu Schwabedissen HE, Präger D, et al,. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 2006; 113: 1114-1122.
37. Pons R, Carrozzo R, Tein I, et al,. Deficient muscle carnitine transport in primary carnitine deficiency. Pediatr Res 1997; 42: 583-587.
38. Georges B, Le Borgne F, Galland S, et al,. Carnitine transport into muscular cells. Inhibition of transport and cell growth by mildronate. Biochem Pharmacol 2000; 59: 1357-1363.
39. Böhmer T, Eiklid K, Jonsen J,. Carnitine uptake into human heart cells in culture. Biochim Biophys Acta 1977; 465: 627-633.
40. Yokogawa K, Yonekawa M, Tamai I, et al,. Loss of wild-type carrier-mediated l -carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. Hepatology 1999; 30: 997-1001.
41. Vaz FM, Wanders RJA,. Carnitine biosynthesis in mammals. Biochem J 2002; 361: 417-429.
42. Fujita M, Nakanishi T, Shibue Y, et al,. Hepatic uptake of γ-butyrobetaine, a precursor of carnitine biosynthesis, in rats. Am J Physiol Gastrointest Liver Physiol 2009; 297: 681-686.
43. Nakanishi T, Fukuyama Y, Fujita M, Shirasaka Y, Tamai I,. Carnitine precursor γ-butyrobetaine is a novel substrate of the Na(+)- and Cl(-)-dependent GABA transporter Gat2. Drug Metab Pharmacokinet 2011; 26: 632-636.
44. Higashi Y, Yokogawa K, Takeuchi N, et al,. Effect of gamma-butyrobetaine on fatty liver in juvenile visceral steatosis mice. J Pharm Pharmacol 2001; 53: 527-533.
45. Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN,. Double-blind, placebo controlled study of acetyl- l -carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 1990; 11: 638-647.
46. No Authors. Acetyl- l -carnitine. Monograph. Altern Med Rev 2010; 15: 76-83.
47. Kuratsune H, Watanabe Y, Yamaguti K, et al,. High uptake of [2-11C]acetyl- l -carnitine into the brain: a PET study. Biochem Biophys Res Commun 1997; 231: 488-493.
48. Kido Y, Tamai I, Ohnari A, et al,. Functional relevance of carnitine transporter OCTN2 to brain distribution of l -carnitine and acetyl- l -carnitine across the blood-brain barrier. J Neurochem 2001; 79: 959-969.
49. Inano A, Sai Y, Nikaido H, et al,. Acetyl- l -carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm Drug Dispos 2003; 24: 357-365.
50. 0,+ in the transport of carnitine through an in vitro model of the blood-brain barrier. J Neurochem 2004; 91: 860-872.
51. Miecz D, Januszewicz E, Czeredys M, et al,. Localization of organic cation/carnitine transporter (OCTN2) in cells forming the blood-brain barrier. J Neurochem 2008; 104: 113-123.
52. Hahn P, Skala JP, Seccombe DW, et al,. Carnitine content of blood and amniotic fluid. Pediatr Res 1977; 11: 878-880.
53. Prasad PD, Huang W, Ramamoorthy S, Carter AL, Leibach FH, Ganapathy V,. Sodium-dependent carnitine transport in human placental choriocarcinoma cells. Biochim Biophys Acta 1996; 1284: 109-117.
54. Grube M, Meyer Zu Schwabedissen H, Draber K, et al,. Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos 2005; 33: 31-37.
55. Shekhawat PS, Yang HS, Bennett MJ, et al,. Carnitine content and expression of mitochondrial beta-oxidation enzymes in placentas of wild-type (OCTN2(+/+)) and OCTN2 null (OCTN2(-/-)) mice. Pediatr Res 2004; 56: 323-328.
56. Robles-Valdes C, McGarry JD, Foster DW,. Maternal-fetal carnitine relationship and neonatal ketosis in the rat. J Biol Chem 1976; 251: 6007-6012.
57. Shennan DB, Grant A, Ramsay RR, Burns C, Zammit VA,. Characteristics of l -carnitine transport by lactating rat mammary tissue. Biochim Biophys Acta 1998; 1393: 49-56.
58. Kwok B, Yamauchi A, Rajesan R, et al,. Carnitine/xenobiotics transporters in the human mammary gland epithelia, MCF12A. Am J Physiol Regul Integr Comp Physiol 2006; 290: R793-R802.
59. Lamhonwah AM, Mai L, Chung C, Lamhonwah D, Ackerley C, Tein I,. Upregulation of mammary gland OCTNs maintains carnitine homeostasis in suckling infants. Biochem Biophys Res Commun 2011; 404: 1010-1015.
60. Jeulin C, Kewin LM,. Role of free l -carnitine and acetyl- l -carnitine in post-gonadal maturation of mammalian spermatozoa. Hum Reprod Update 1996; 2: 87-102.
61. Enomoto A, Wempe MF, Tsuchida H, et al,. Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem 2002; 277: 36262-36271.
62. --coupled active transport of carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes. J Physiol 2001; 532: 297-304.
63. Kobayashi D, Goto A, Maeda T, Tsuji A, Tamai I,. OCTN2-mediated carnitine transport across the blood-testis barrier. Reproduction 2005; 129: 729-736.
64. Maeda T, Goto A, Kobayashi D, Tamai I,. Transport of organic cations across the blood-testis barrier. Mol Pharm 2007; 4: 600-607.
65. Kobayashi D, Irokawa M, Maeda T, Tsuji A, Tamai I,. Carnitine/organic cation transporter OCTN2-mediated transport of carnitine in primary-cultured epididymal epithelial cells. Reproduction 2005; 130: 931-937.
66. Rodríguez CM, Labus JC, Hinton BT,. Organic cation/carnitine transporter, OCTN2, is differentially expressed in the adult rat epididymis. Biol Reprod 2002; 67: 314-319.
67. Yakushiji K, Kai S, Yamauchi M, Kuwajima M, Osada Y, Toshimori K,. Expression and distribution of OCTN2 in mouse epididymis and its association with obstructive azoospermia in juvenile visceral steatosis mice. Int J Urol 2006; 13: 420-426.
68. Cotton LM, Rodriguez CM, Suzuki K, Orgebin-Crist MC, Hinton BT,. Organic cation/carnitine transporter, OCTN2, transcriptional activity is regulated by osmotic stress in epididymal cells. Mol Reprod Dev 2010; 77: 114-125.
69. Toshimori K, Kuwajima M, Yoshinaga K, Wakayama T, Shima K,. Dysfunctions of the epididymis as a result of primary carnitine deficiency in juvenile visceral steatosis mice. FEBS Lett 1999; 446: 323-326.
70. Kobayashi D, Tamai I, Yoshida K, et al,. Transport of carnitine and acetylcarnitine by octn2 and octn3 into epididymal spermatozoa. Reproduction 2007; 134: 651-658.
71. Tein I,. Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 2003; 26: 147-169.
72. Sugiura T, Kato S, Shimizu T, et al,. Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver. Drug Metab Dispos 2010; 38: 1665-1672.
73. Xuan C, Zhang BB, Yang T, Deng KF, Li M, Tian RJ,. Association between OCTN1/2 gene polymorphisms (1672C-T, 207G-C) and susceptibility of Crohn's disease: a meta-analysis. Int J Colorectal Dis 2012; 27: 11-19.
74. Moffatt MF, Gut IG, Demenais F, et al,. GABRIEL Consortium. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363: 1211-1221.
75. Horvath G, Schmid N, Fragoso MA, et al,. Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am J Respir Cell Mol Biol 2007; 36: 53-60.
76. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I,. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm 2010; 7: 187-195.
77. Wu X, Prasad PD, Leibach FH, Ganapathy V,. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 1998; 246: 589-595.
78. Inano A, Sai Y, Kato Y, Tamai I, Ishiguro M, Tsuji A,. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition. Drug Metab Pharmacokinet 2004; 19: 180-189.
79. Ohashi R, Tamai I, Yabuuchi H, et al,. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 1999; 291: 778-784.
80. Ganapathy ME, Huang W, Rajan DP, et al,. Beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 2000; 275: 1699-1707.
81. Kano T, Kato Y, Ito K, Ogihara T, Kubo Y, Tsuji A,. Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. Drug Metab Dispos 2009; 37: 1009-1016.
82. Hu S, Franke RM, Filipski KK, et al,. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008; 14: 3141-3148.
83. Grigat S, Fork C, Bach M, et al,. The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. Drug Metab Dispos 2009; 37: 330-337.
84. Ekins S, Diao L, Polli JE,. A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. Mol Pharm 2012; 9: 905-913.
85. Ohashi R, Tamai I, Inano A, et al,. Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein. J Pharmacol Exp Ther 2002; 302: 1286-1294.
86. Ohashi R, Tamai I, Nezu Ji J, et al,. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol 2001; 59: 358-366.
87. Glube N, Closs E, Langguth P,. OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1). Mol Pharm 2007; 4: 160-168.
88. Nakanishi T, Haruta T, Shirasaka Y, Tamai I,. Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab Dispos 2010; 39: 117-122.
89. Mo JX, Shi SJ, Zhang Q, Gong T, Sun X, Zhang ZR,. Synthesis, transport and mechanism of a type I prodrug: l -carnitine ester of prednisolone. Mol Pharm 2011; 8: 1629-1640.
90. Ehrhardt C, Kneuer C, Bies C, Lehr CM, Kim KJ, Bakowsky U,. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm Pharmacol Ther 2005; 18: 165-170.
91. Lips KS, Volk C, Schmitt BM, et al,. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 2005; 33: 79-88.
92. Mukherjee M, Pritchard DI, Bosquillon C,. Evaluation of air-interfaced Calu-3 cell layers for investigation of inhaled drug interactions with organic cation transporters in vitro. Int J Pharm 2012; 426: 7-14.
93. Ludwig T, Riethmüller C, Gekle M, Schwerdt G, Oberleithner H,. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004; 66: 196-202.
94. Ciarimboli G,. Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 2011; 7: 159-174.
95. Grothey A,. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30 (4 Suppl 15): 5-13.
96. Brass EP, Mayer MD, Mulford DJ, Stickler TK, Hoppel CL,. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clin Pharmacol Ther 2003; 73: 338-347.
97. Opala G, Winter S, Vance C, Vance H, Hutchison HT, Linn LS,. The effect of valproic acid on plasma carnitine levels. Am J Dis Child 1991; 145: 999-1001.
98. Okamura N, Ohnishi S, Shimaoka H, Norikura R, Hasegawa H,. Involvement of recognition and interaction of carnitine transporter in the decrease of l -carnitine concentration induced by pivalic acid and valproic acid. Pharm Res 2006; 23: 1729-1735.
99. Ohnishi S, Okamura N, Sakamoto S, et al,. Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. Drug Metab Pharmacokinet 2008; 23: 293-303.
100. Todesco L, Bodmer M, Vonwil K, Häussinger D, Krähenbühl S,. Interaction between pivaloylcarnitine and l -carnitine transport into L6 cells overexpressing hOCTN2. Chem Biol Interact 2009; 180: 472-477.